HU

Hungary

Key Insights

  • 1

    No psychedelic therapy is approved in Hungary; patient access appears limited to standard care and any esketamine use under ordinary medicines rules, not a dedicated psychedelic pathway.

  • 2

    The database shows 6 Hungarian trials, 0 active, 0 research organisations, and only esketamine and placebo studied so far.

  • 3

    Hungary’s clearest historical marker is not psychedelic: a 2021 nationwide study found 8.3% treatment-resistant depression in 99,531 Hungarian MDD patients.

  • 4

    Momentum is thin: with no active trials or named organisations, the field is waiting on fresh sponsorship, likely around ketamine-derived depression programmes.

Medical Only (Private)

Reimbursed Care Access

Hungary maintains a restrictive legal regime for classic psychedelics: most tryptamines, phenethylamines and plant/fungal preparations (psilocybin, DMT, 5‑MeO‑DMT, MDMA, mescaline, ibogaine, ayahuasca, 2C‑X) are controlled and have no routine medical availability outside approved clinical research. Esketamine (Spravato) is authorised in the EU and listed in Hungarian product databases and can be delivered through licensed medical services; reimbursement pathways exist but are limited and administratively gated. Ketamine is legally available as an anaesthetic and is used off‑label in psychiatric practice (including private clinics), but routine public reimbursement for psychiatric ketamine therapy is not established and is handled case‑by‑case (named‑patient or special financing).

Full guide →

Quick Indicators

Active Trials
0
Total Trials
6
Organizations
0
Events
0
Reimbursement Guide→All Countries→Clinical Trials→Research Papers→

Clinical Trials

Active and completed clinical trials investigating psychedelic-assisted therapies in Hungary.

CompletedPhase IV

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Started
CompletedPhase III

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/​Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Started
CompletedPhase II

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Started
CompletedPhase III

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

Started
CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Started
CompletedPhase III

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Started